2seventy bio Management

Management criteria checks 0/4

2seventy bio's El consejero delegado es Chip Baird , nombrado en Jan 2024, tiene un mandato de menos de un año. posee directamente 0.12% de las acciones de la empresa, con un valor de $308.35K . La antigüedad media del equipo directivo y del consejo de administración es de 0.3 años y 2.3 años, respectivamente.

Key information

Chip Baird

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.1%
Management average tenure	less than a year
Board average tenure	2.5yrs

Recent management updates

Recent updates

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

Aug 10

CEO Compensation Analysis

How has Chip Baird's remuneration changed compared to 2seventy bio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$218m
Sep 30 2023	n/a	n/a	-US$184m
Jun 30 2023	n/a	n/a	-US$180m
Mar 31 2023	n/a	n/a	-US$215m
Dec 31 2022	n/a	n/a	-US$254m
Sep 30 2022	n/a	n/a	-US$292m
Jun 30 2022	n/a	n/a	-US$284m
Mar 31 2022	n/a	n/a	-US$291m
Dec 31 2021	US$2m	US$491k	-US$292m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$320m
Mar 31 2021	n/a	n/a	-US$222m
Dec 31 2020	US$2m	US$475k	-US$120m

Compensación vs. Mercado: Datos insuficientes para determinar si la remuneración total de Chip es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: Chipha aumentado mientras la empresa no es rentable.

CEO

Chip Baird (51 yo)

less than a year

Tenure

US$2,441,131

Compensation

Mr. William D. Baird III, also known as Chip, serves as Chief Executive Officer of 2seventy bio, Inc. since January 2024. He was Principal Financial Officer and Principal Accounting Officer at bluebird bio...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nick Leschly	President & Director	2.9yrs	US$6.08m	2.68% $ 8.0m
Philip Gregory	Chief Scientific Officer	2.4yrs	US$2.53m	0.20% $ 582.6k
William Baird	Chief Executive Officer	less than a year	US$2.44m	0.12% $ 344.0k
Vicki Eatwell	Chief Financial Officer	less than a year	no data	no data
Jessica Snow	Senior VP of Quality and Head of Operations	less than a year	no data	no data
Susan Abu-Absi	Chief Technology Officer	no data	no data	no data
Teresa Jurgensen	Senior VP	no data	no data	no data
Kerri Jensen	Head of People & Culture	less than a year	no data	no data
Jenn Snyder	Senior Vice President of Corporate Affairs	no data	no data	no data
Steven Bernstein	Chief Medical Officer	2.2yrs	no data	no data
Michael Certo	VP & Head of Genome Editing	no data	no data	no data

0.5yrs

Average Tenure

51yo

Average Age

Equipo directivo experimentado: TSVTEl equipo directivo de la empresa no se considera experimentado ( 0.3 años de permanencia media), lo que sugiere un nuevo equipo.

Board Members

Name	Position	Tenure	Compensation	Ownership
Nick Leschly	President & Director	no data	US$6.08m	2.68% $ 8.0m
Daniel Lynch	Independent Chairman of the Board	2.5yrs	US$327.57k	0.025% $ 73.3k
Eli Casdin	Independent Director	less than a year	no data	no data
Charles Newton	Independent Director	less than a year	no data	no data
Marcela Maus	Independent Director	2.5yrs	US$242.42k	0.010% $ 30.1k
Denice Torres	Lead Independent Director	2.5yrs	US$330.51k	0.021% $ 62.4k
Sarah J. Glickman	Independent Director	2.5yrs	US$253.54k	0.010% $ 30.1k
Wei Lin	Independent Director	1.1yrs	no data	no data

2.5yrs

Average Tenure

53yo

Average Age

Junta con experiencia: TSVTno se consideran experimentados ( 2.2 años de permanencia media), lo que sugiere un nuevo consejo.

2seventy bio Management

Management criteria checks 0/4

Key information

Recent management updates

2seventy bio, Inc. Announces Board Appointments

2seventy bio, Inc. Announces Executive and Board Changes

President recently sold US$280k worth of stock

High number of new and inexperienced directors

2Seventy Bio, Inc. Announces Resignation of Nick Leschly as CEO

President recently sold US$51k worth of stock

Recent updates

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

Consensus revenue estimates fall by 24%

New minor risk - Shareholder dilution

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.40 loss per share (vs US$1.76 loss in 3Q 2022)

Forecast to breakeven in 2025

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Price target increased by 33% to US$10.67

2seventy bio, Inc. Announces Executive and Board Changes

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

President recently sold US$280k worth of stock

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

High number of new and inexperienced directors

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2Seventy Bio, Inc. Does Not Expect to Achieve the Original Revenue Guidance for 2023

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces Resignation of Nick Leschly as CEO

President recently sold US$51k worth of stock

Consensus estimates of losses per share improve by 15%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President recently sold US$55k worth of stock

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target decreased by 11% to US$25.00

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 12%

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

President recently sold US$69k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

Chief Operating Officer recently sold US$108k worth of stock

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients

2seventy bio Prospects

Consensus revenue estimates fall by 16%

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3

President recently sold US$89k worth of stock

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

President recently sold US$75k worth of stock

Consensus revenue estimates fall by 13%

2Seventy Bio, Inc. Announces Resignation of William Sellers to Its Board of Directors

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus forecasts updated

2Seventy Bio, Inc. to Present New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, At the AACR Annual Meeting

Consensus forecasts updated

2seventy bio, Inc. announced that it has received $170.000009 million in funding from a group of investors

Consensus estimates of losses per share improve by 34%